Cellectar Biosciences Inc (NASDAQ:CLRB) CEO James V. Caruso sold 34,000 shares of Cellectar Biosciences stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $1.20, for a total value of $40,800.00. Following the transaction, the chief executive officer now owns 213,548 shares of the company’s stock, valued at $256,257.60. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Cellectar Biosciences Inc (NASDAQ:CLRB) remained flat at $$1.17 during trading hours on Wednesday. The company had a trading volume of 322,350 shares, compared to its average volume of 257,440. The firm has a market capitalization of $18.98, a price-to-earnings ratio of -1.09 and a beta of 0.75. Cellectar Biosciences Inc has a 1 year low of $1.06 and a 1 year high of $2.70.
Several brokerages have recently commented on CLRB. ValuEngine upgraded Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research upgraded Cellectar Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th.
COPYRIGHT VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/03/14/cellectar-biosciences-inc-clrb-ceo-sells-40800-00-in-stock.html.
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.